ESTRO 2025 - Abstract Book

S1963

Clinical - Urology

ESTRO 2025

change in EPIC score vs baseline for sexual function (-6.8 vs -11.7, p=0.096) and borderline significant smaller mean change in bowel (-0.15 vs -3.29, p=0.06) and urinary irritative/obstructive (-1.77 vs -6.25, p=0.07) domains ( Figure 1 ). When assessing literature-based thresholds, 3-month minimally important difference (MID) change in bowel domain was significantly reduced with NV-SAbR (19% vs 37%, p=0.03). Amongst patients treated at higher 45Gy RT dose (n=43), MID changes in urinary obstructive/irritative (26% vs 58%, p=0.04) and incontinence (11% vs 40%, p=0.04) domains also significantly favored NV-SAbR.

Conclusion: